Safety and Efficacy of 20 Cycles of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Current randomized controlled data ([1][1] , [2][2]) demonstrate the safety and efficacy of 6 cycles of [177Lu]Lu-PSMA-617 therapy in men with metastatic castration-resistant prostate cancer. In our first phase 2 trial ([3][3]), 15 of 30 patients received additional cycles; 11 (73%) had a subsequent